The high-risk patient group classified by our predictive model had inferior MRs compared with the low-risk patient group in the validation cohort. (A) The high-risk (HR-GES) patient group classified by our predictive model (n = 9) had significantly inferior cumulative incidence (44%) of MMRs (>3 log reduction of BCR-ABL1 transcript value) by 24 months compared with the low-risk (LR-GES) patient group (78%; n = 79). (B) The EMR failure patient group defined by BCR-ABL1 percentage at 3 months (n = 11) had significantly inferior cumulative incidence of MMRs (>3 log reduction of BCR-ABL1 transcript value) by 24 months (45%) compared with the EMR achievement patient group (79%; n = 77). (C) The high-risk patient group classified by our predictive model (n = 9) had significantly inferior cumulative incidence of deep MR (MR4.5; >4.5 log reduction of BCR-ABL1 transcript value) by 5 years (0%) when compared with the low-risk patient group (63%; n = 79). (D) The EMR failure patient group defined by BCR-ABL1 percentage at 3 months (n = 11) had significantly inferior cumulative incidence of MR4.5 by 5 years (30%) compared with the EMR achievement patient group (61%; n = 77). All statistical analyses were performed using the Fine and Gray test.